Entos Pharmaceuticals has received funding for phase I clinical trials of the COVID-19 DNA vaccine.

Biotech company Enters Pharmaceuticals recently announced that it has received up to $5 million from the National Research Council of Canada's Industrial Research Assistance Program (NRC IRAP).
Entos has developed a Fusogenix DNA vaccine called Covigenix, which in preclinical studies induces strong meso-antibody responses and T-cell responses to SARS-CoV-2, the virus that causes COVID-19.
support from NRC IRAP will help Enters' COVID-19 DNA vaccine research enter Phase I clinical trials.
Lewis, chief executive of Entos Pharmaceuticals, said: "Entos is proud to be one of the Canadian innovation companies supported by the NRC IRAP.
We are pleased to use this funding to advance Covigenix's Phase I human clinical trials."
urgent need to develop and produce safe and effective vaccines against COVID-19 for Canadians and the global population to ensure lasting protection.
Entos is actively seeking financial support from the government and investors to advance Phase II and Phase III human clinical trials and accelerate the growth of Covigenix GMP's production capacity.
.